WATERTOWN, Mass.--(BUSINESS WIRE)--Gentronix Limited, a genotoxicity product and services provider, and Apredica, an ADME-Tox contract research laboratory, today announced a strategic alliance to provide drug-discovery support services in the area of predictive toxicology. The objective of the alliance is to reduce the failure rate of drugs in late development, particularly due to toxicity, thereby improving the efficiency of drug discovery and increasing assurance that new drugs are safe.
